Apogee Therapeutics, Inc. APGE Proceeds From Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs
Proceeds From Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs at other companies
Other financials
Where this comes from
Reported directly by Apogee Therapeutics, Inc. in its filing.
Tagged under the XBRL concept apge:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts.
The official record: Apogee Therapeutics, Inc.’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →
Ask your AI about Apogee Therapeutics, Inc.'s proceeds from issuance of common stock and pre funded warrants net of issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Apogee Therapeutics, Inc.'s proceeds from issuance of common stock and pre funded warrants net of issuance costs?
- Apogee Therapeutics, Inc. (APGE) reported proceeds from issuance of common stock and pre funded warrants net of issuance costs of $81.01M in Q4 2025.
- How has Apogee Therapeutics, Inc.'s proceeds from issuance of common stock and pre funded warrants net of issuance costs changed year-over-year?
- Apogee Therapeutics, Inc.'s proceeds from issuance of common stock and pre funded warrants net of issuance costs decreased by 28.0% year-over-year, from $112.49M to $81.01M.
- What is the long-term trend for Apogee Therapeutics, Inc.'s proceeds from issuance of common stock and pre funded warrants net of issuance costs?
- Over 2 years (2023 to 2025), Apogee Therapeutics, Inc.'s proceeds from issuance of common stock and pre funded warrants net of issuance costs has grown at a 1.4% compound annual growth rate (CAGR), from $315.39M to $324.05M.
- What does proceeds from issuance of common stock and pre funded warrants net of issuance costs mean?
- This represents the total cash inflows generated from the primary issuance of common equity or pre-funded warrants, net of any associated underwriting or legal costs. It serves as a key indicator of a company's ability to raise capital from public markets to fund research, development, or operational expansion. For biotechnology firms, this is a critical measure of financial runway and capital market access.